Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Two Pacts Target Oligonucleotides
by Michael McCoy
November 24, 2014
| A version of this story appeared in
Volume 92, Issue 47
Johnson & Johnson’s Janssen Biotech unit and the biotech firm Geron are joining to develop Geron’s imetelstat, a modified oligonucleotide in early-phase development as an oncology treatment. Janssen will pay Geron $35 million up front and up to $900 million in milestone payments. Separately, AstraZeneca and Isis Pharmaceuticals are forming an alliance to discover new delivery methods for antisense oligonucleotides. The partners intend to build on Isis’s ligand conjugation antisense technology, which they say lowers the dose needed for liver targets by about 10-fold.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter